SerraEzyme™ 80,000IU - New Super Tablet - 90 Quad Strength Tablet: £18.95
Other Ingredients: HPMCP (Enteric Coating), Microcrystaline Cellulose, Magnesium Stearate.
http://www.goodhealth.nu/uk/1745
Affiliate Address: Click this link to buy your Serrapeptase through the
New-NHS affiliate program.
From Goodhealth Naturally!
To support the cause please buy your Serrapeptase from
Good Health Naturally by clicking the link above.
We strongly recommend the 4 for 3 offer of the
Quad Strength Tablets which works out to £14.21 per bottle & free postage.
This is probably the best deal on the market for price, strength and quality.
Buy 4 pots and give some to your friends.
SerraEzyme™
80,000IU - New Super Tablet - 90 Quad Strength Tablet: £18.95
Other Ingredients: HPMCP (Enteric
Coating), Microcrystaline Cellulose, Magnesium Stearate.
RETAIL
OFFER: Buy 3 bottles of SerraEzyme (80,000iu) and receive an extra FREE bottle
£56.85
=
£14.21 each
Other
Serrapeptase Addresses
http://www.goodhealth.nu/serrapeptase/book.html
Serrapeptase the Book: The Miracle Enzyme: by Robert Redfern:
The website contains loads of interesting info about the effectiveness of
Serrapeptase.
“You will probably know that Chronic
Inflammation is now considered by the scientific community to be a major cause
of the chronic (long-term) diseases.
Inflammation measured by C-Reactive Protein
(CRP) is produced by the liver, when inflammation is present in the blood
stream.
Chronic inflammation is involved in diseases
as diverse as arthritis, arteriosclerosis, cancer, heart valve dysfunction,
diabetes, cancer, congestive heart failure and Alzheimer’s. In those people
with premature aging, degenerative diseases all are seen to have high CRP
levels.
http://www.global-unity.com/NewNHS.htm
New-NHS
web-page: under construction.
Aspirin,
Lactose & Serrapeptase:
My Experience of Serrapeptase.
By John A Webb: Founder of the New-NHS.
1 June 2007.
NB:
Pharmaceutical Aspirin (the stuff you buy at the chemists) contains too many
additives (always read the leaflet) including Lactose.
I am ‘Lactose Intolerant’, if I take anything containing large doses of
lactose, ie milk or prescribed medication, I suffer from severe Sinus &
Irritable Bowl Syndrome (IBS).
5
of the 7 pharmaceutical medications prescribed and taken after my heart attack
(including aspirin), contained large amounts of Lactose, (only as a
bulking-binding agent, not for medical reasons) which basically caused
inflammation, ie Sinusitis & IBS.
Also
in the 7 medications there were 100 other pharmaceutical drugs, many with very
harmful side affects. These are included only to enable the pharmaceutical
companies to claim their patents.
I asked my GP and the Hospital Pharmacist for substitute drugs without Lactose,
the HP managed to find a substitute for only 1 of the lactose-loaded drugs.
The combination of Sinusitis & the ‘Beta Blocker’ also caused a great
deal of ‘mental confusion’, which was very worrying. At several stages I
thought I might be developing Alzheimer’s, very worrying and not very
conducive to cardiac recovery.
After
taking Serrapeptase for about 6 months, I feel that the arterial plaque has been
completely eliminated from my body, however the only way of testing this is with
a EBCT scan, as discussed and proposed in the New-NHS webpage at:
http://www.global-unity.com/NewNHS.htm
13
Sept 2007: About a week ago I decided to stop taking the pharmaceutical drugs
completely, including aspirin, and rely on a regular daily ‘maintenance’
dose, about 3 pills a day of Serrapeptase.
About
2 to 3 days later the mental confusion disappeared and I noticed a wonderful
change in my mental abilities and memory retention, probably better than before
I had the heart attack.
To me this implies that the Serrapeptase has not only cleared and healed the
Coronary Plaque but has also cleared all arteriosclerosis (arterial plaque) and
other ‘blockages’ from the brain and every other organ (liver etc) in my
body. Tank de Lord! & Serrapeptase.
14
April 2008: I have recently had a complete blood test done through the NHS.
I was absolutely amazed and delighted to find that my blood
Cholesterol ratio was 3.1.
All my other
blood & liver functions were also well within the recommended parameters.
Before
my heart attack in Jan 2007, my cholesterol level was 5.2, not high, but then I
had a Heart Attack?!? This is the main reason why I have proposed the New-NHS,
to find out why, and to prevent others suffering the same consequences.
Around
Dec 2007 I ‘developed’ a painful touch of Tendonitis of the Achilles (ankle)
tendon.
Apparently there is no medical cure for this problem, it’s just a case of rest
and ‘don’t walk anywhere’.
Tendonitis is one of those really annoying and debilitating chronic (long term)
pains that are with you 24/7, even when you’re trying to sleep.
I
tried several stronger pharmaceutical anti-inflammatory, and some natural
therapy anti-inflammatories, including one that claimed to cure tendonitis in 3
days.
After
about 2 month of this annoying agony, I decided to increase my Serrapeptase dose
to about 9 a day. Within a week I noticed a marked improvement, now I only have
a very slight tenderness in my ankle if I walk any great distance, but none of
the chronic pain and symptoms.
For these reasons I would strongly recommend, or even
insist,
that everyone, but especially my friends, should take Serrapeptase immediately.
Given that there are absolutely no side affects, it would be ‘Churlish’ or
even stupid not to. JW.
If
you have any questions or comments, please email them to me at: johnwebb2003@aol.com
http://www.natureswaves.co.uk/serrapeptase_anti-inflammatory.html
Article
I have reprinted this article
below because it has a dark background on the web-page and is difficult to read.
·
About
Serrapeptase
Background.
Our knowledge of Serrapeptase
started with the silkworm. This amazing creature protects itself in a chrysalis
whilst developing. When the time comes for it to move on, it has to get out of
the chrysalis. It does this by secreting a fluid, which dissolves the chrysalis
(silk cacoon). Having discovered this, scientists looked at the enzyme and how
it could help human beings. The enzyme was serratia peptidase, a
proteolytic enzyme isolated from the micro-organism, Serratia E15, now
manufactured (without the silk worm) commercially today through fermentation, as
Serrapeptase. It has been in use for some 25 years though Europe and Asia as a
viable alternative to salicylates, ibuprofen and the more potent Non-Steroidal
Anti-inflammatory Drugs (NSAIDS). Unlike these drugs, Serrapeptase
is a physiological agent with no inhibitory effects on prostaglandins and is
devoid of gastrointestinal side effects. It is standard treatment in Germany and
other European countries for the treatment of inflammatory and traumatic
swellings.
Serrapeptase is an immunologically active enzyme that is
completely bound to the alpha 2 macroglobulin in biological fluids. Histologic
studies reveal powerful anti-inflammatory effects of this naturally occurring
enzyme.
Serrapeptase
digests non-living tissue, blood clots, cysts, and arterial plaque and
inflammation in all forms. The late German physician Dr. Hans Nieper used
Serrapeptase to treat arterial blockage in his coronary patients. Serrapeptase
protects against stroke and is
more effective and quicker than EDTA chelation treatments in removing arterial
plaque. He also reports that Serrapeptase dissolves blood clots and
causes varicose veins to shrink or diminish. Dr. Nieper told of a woman
scheduled for hand amputation and a man scheduled for bypass surgery who both
recovered quickly without surgery after treatment with Serrapeptase.
Studies with Serrapeptase in the treatment of coronary
artery disease are relatively new. Hans A. Nieper, M.D., an internist from
Hannover, Germany, studied the effects of Serrapeptase on plaque accumulations
in the arteries. The
formation of plaque involves deposits of fatty substances, cholesterol, cellular
waste products, calcium and fibrin (a clotting material in the blood) on the
inner lining of the arteries. Excessive plaque results in partial or
complete blockage of the blood's flow through an artery, resulting in
arteriosclerosis, or hardening of the arteries, and an ensuing stroke or heart
attack. The evidence to support Serrapeptase's role in preventing plaque
build-up is anecdotal. Still, further studies are called for in this area as
Nieper's research indicated
that the protein-dissolving action of Serrapeptase will gradually break down
atherosclerotic plaques.
However, a wealth of information exists regarding its anti-inflammatory
properties. Serrapeptase
has been used as an anti-inflammatory agent in the treatment of chronic
sinusitis, to improve the elimination of bronchopulmonary secretions,
traumatic injury (e.g. sprains and torn ligaments), post-operative inflammation
and to facilitate the therapeutic effect of antibiotics in the treatment of
infections. In the urological field, Serrapeptase has been used successfully for
cystitis and epididymitis.
Post-surgical
treatment.
In one double-blind study of Serrapeptase conducted by Esch et al at the German
State Hospital in Ulm, 66 patients with fresh rupture of the lateral ligament
treated surgically were divided in three randomised groups. In the group
receiving the test substance, the swelling had decreased by 50% on the third
post-operative day, while in the other two control groups (elevation of the leg,
bed rest, with or without the application of ice), no reduction in swelling had
occurred at that time. The difference was of major statistical significance.
Decreasing pain correlated for the most part with the reduction in swelling. The
patients receiving Serrapeptase became pain-free more rapidly than the control
groups. By the 10th day, all patients were free of pain in the Serrapeptase-treated
group. The therapeutic daily dose was 1-2 tablets (5 mg) 3 times daily.
Cystic
Breast Disease.
In another double-blind study, Serrapeptase, was evaluated in a group of 70
patients with evidence of cystic breast disease. These patients were randomly
divided into a treatment group and a placebo group. Serrapeptase was noted to be
superior to placebo for improvement of breast pain, breast swelling and
induration with 85.7% of the patients who received Serrapeptase reporting
moderate to marked improvement. No adverse reactions were reported with the use
of Serrapeptase. The use of enzymes with fibrinolytic, proteolytic and anti-edemic
activities for the treatment of inflammatory conditions of the ear, nose and
throat has gained increasing support in recent years.
Ear
Nose and Throat Disorders.
In a third double-blind study, 193 subjects suffering from acute
or chronic ear, nose or throat disorders were evaluated. Treatment with
Serrapeptase lasted 7-8 days, two 5 mg tabs, t.i.d. After 3-4 days
treatment, significant symptom regression was observed in the Serrapeptase-treated
group, while this was not noted in the control group. Patients suffering from
laryngitis, catarrhal rhinopharyngitis and sinusitis noted markedly rapid
improvement. The physicians' assessments of efficacy of treatment were excellent
or good for 97.3% of patients treated with Serrapeptase compared with only 21.9%
of those treated with placebo. In a similar study of chronic bronchitis,
conducted by a team of otolaryngolosists, the Serrapeptase-treated group showed
excellent results compared with the placebo group in the improvement of
loosening sputum, frequency of cough and expectoration. Other improvements
included the posterior nasal hydrorhea and rhinostenosis. The administration of
Serrapeptase reduces the viscosity of the nasal mucus to a level at which
maximal transport can be achieved.
Improved
efficacy of antibiotics.
It has also been demonstrated that the simultaneous use of the peptidase and an
antibiotic results in increased concentrations of the antibiotic at the site of
the infection. The mechanisms of action of Serrapeptase, at the sites of various
inflammatory processes consists fundamentally of a reduction of the exudative
phenomena and an inhibition of the release of the inflammatory mediators. This
peptidase induces fragmentation of fibrinose aggregates and reduces the
viscosity of exidates, thus facilitating drainage of these products of the
inflammatory response and thereby promoting the tissue repair process. Studies
suggest that Serrapeptase has a modulatory effect on specific acute phase
proteins which are involved in the inflammatory process. This is substantiated
by a report of significant reductions in C3 and C4 complement, increases in
opsonizing protein and reductions in concentrations of haptoglobulin, which is a
scavenger protein that inhibits lysosomal protease.
Absorption.
The intestinal absorption of Serrapeptase has been reported by several re-search
groups. Serrapeptase
is well absorbed orally when formulated with an enteric coating. It is known
that proteases and peptidases are only absorbed in the intestinal area.
These enzymes are mobilized directly to the blood and are not easily detectable
in urine. Other enzymes with structural similarities have been reported to be
absorbed through the intestinal tract. Chymotrypsin
is transported into the blood from the intestinal lumen. Horseradish
peroxidase can cross the mucosal barrier of the intestine in a
biologically and immunologically active form. Several studies have appeared so
far which refer to the systemic effects of orally given proteases and peptidases
(e.g. Serrapeptase), such as repression of edema and repression of blood vessel
permeability induced by histamine or bradykinin. These enzymes also effect the
kallikrein-kinin system and the complement system, thus modifying the
inflammatory response.
Summary.
In vitro and in viuo studies reveal that Serrapeptase has an
aspecific, anti-inflammatory effect, superior to that of other proteolytic
enzymes (ie Asperin JW). A review of the scientific literature, including
a series of controlled, clinical trials with large patient groups, suggests that
Serrapeptase is useful for a broad range of inflammatory conditions. If
one considers the fact that anti-inflammatory agents are among the most widely
prescribed drugs, the use of a safe, proteolytic enzyme such as Serrapeptase
would be a welcome addition to the physician's armamentarium of physiologic
agents.
l.
Kee WH. Tan SL, Lee V. Salmon YM. The treatment of breast engorgement with
Serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore Med
J. 1989:30(1):48-54.
2. Mizukoshi, D. et al. A double-blind clinical study of Serrapeptase in the
treatment of chronic sinusitis. Igaku Ayrni 109:50-62.1979.
3. Carratu, L. et al. Physio-chemical and rheological research on mucolytic
activity of Serrapeptase in chronic broncho-pneumopathies. Curr. Ther. Res.
28(6):937-951. 1980.
4. Braga, P.C. et al. Effects of Serrapeptase on muco-ciliary clearance in
patients with chronic bronchitis. Curr. Ther. Res. 29(5):738-744,1981.
5. Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic
inflammation of otorhinolaryngology pathology: a multicentre, double-blind
randomized trial versus placebo. J. int. Med. Res. 18(5):379-388,1990.
6. Kakinumu, A. et al. Regression of fibrinolysis in scalded rats by
administration of Serrapeptase. Biochem. Pharmacol. 31:2861-2866,1982.
7. Marly, M. Enzymotherapie anti-inflammatoire a l'aide de la Serrapeptase:
resultats cliniques en traumatologie et en ORL. C R Therapeut. 3:9-19,1985.
8. Odagiri, J. et al. Clinical applications of Serrapeptase in sinusitis. Med.
Consult. New Remedy 6:201-209, 1979.
9. Yamazaki, J. et al. Anti-inflammatory activity of TSP, a protease produced by
a strain of Serratia. Folia Pharmacol. Japon. 6^302-314,1967.
10. Harad~, Y. Clinical efficacy of Serrapeptase on buccal swelling after
radical operation for chronic sinusitis. Igaku Ayumi 123:768-778.1982.
11. I. Matsudo, A. et at. Effect of Serrapeptase (Danzen) on inflammatory edema
following operation for thyropid disease. Med. Consult. New Remedy 18:171-175,
1981.
12. Fujitani, T. et al. Effect of anti-inflammatory agent on transfer of
antibiotics to the maxillary sinus mucosa in chronic sinusitis. Otorhinolaryngol.
Clin. North Am. 66:557-565. 1976.
13. Tago. T. and Mitsui, S. Effects of Serrapeptase in dissolution of sputum,
especially in patients with bronchial asthma. Jap. Clin. Exp. Med. 49:222-228,
1972.
14. Mazzonie, A. et al. Evaluation of Serrapeptase in acute or chronic
inflammation of otorhinolaryngology pathology: a multicentre, double-blind
randomized trial versus placebo. J. int. Med. Res. 18(5):379-388,1990.
15. Kase, Y. et al. A new method for evaluating mucolytic expectorant activity
and its application. II. Application to two proteolytic enzymes, Serrapeptase
and seaprose. Arzneimittelforschung 32:374-378,1982.
16. Marriott, C. Modification of the rheoloaical properties of mucus by drugs.
Adv. Exp. Med. Biol. 144^75-84, 1982.
17. Majima. Y. et al. Effects of orally administered drugs on dynamic
viscoelasticity of human nasal mucus. Am. Rev. Respit. Dis. 141:79-83.1990.
18. Miyata, K. Intestinal absorption of Serrapeptase. J ApplBiochem.
1980:2:111-16.
19. Aso T. et al. Breast engorgement and its treatment: Clinical effects of
Danzen (Serrapeptase) an anti-inflammatory enzyme preparation. The world of
Obstetrics and Gynecology (Japanese). 1981:33:371-9.
20. Esch PM, Gemgross H. Fabian A. Reduction of postoperative swelling.
Objective measurement of swelling of the upper ankle joint in treatment with
Serrapeptase-a prospective study (German). FortschrMed. 1989; 107(4):67-8, 71-2.
21. Majima Y, lnagaki M, Hirata K. Takeuchi K, M orishita A, Sakakura Y. The
effect of an orally administered proteolytic enzyme on the elasticity and
viscosity of nasal mucus. Arch Otorhinolaryngol. 1988;244(6):355-9.
22. Selan L, Berlutti F, Passariello C. Comodi-Ballanti MR, Thaller MC.
Proteolytic enzymes: a new treatment strategy for prosthetic infections?
Antimicrob Agents Cheroother. 1993; 37(12):2618-21.
23. Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu
H, Hirata M, Arai T, et al. Augmentation by Serrapeptase of tissue permeation by
cefotiam (Japanese). Jpn JAntibiot. 1986; 39(3):761-71.
----------------------------------------------------------------------------
Contact
Details:
John A
Webb
www.Global-Unity.com
http://www.global-unity.com/NewNHS.htm
email:-
Johnwebb2002@aol.com